{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:13:04Z","timestamp":1788783184127,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Breast cancer is the most common malignancy among women worldwide. A notable subset of patients presents with\n                      <jats:italic>de-novo<\/jats:italic>\n                      stage IV breast cancer at initial diagnosis, meaning metastatic lesions are already present. These patients typically receive primary systemic therapy aimed at palliative care, with locoregional treatment remaining controversial. Although numerous retrospective studies have suggested that resection of the primary tumor may improve survival, prospective randomized trials have not demonstrated a clear benefit, and routine surgical intervention is not generally advocated. This paper aims to review and discuss the research progress regarding locoregional surgical treatment for\n                      <jats:italic>de-novo<\/jats:italic>\n                      stage IV breast cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>\n                      Recent retrospective and prospective studies on locoregional surgery for\n                      <jats:italic>de-novo<\/jats:italic>\n                      stage IV breast cancer were searched, with a focus on prospective randomized controlled trials (RCTs). The collected evidence was reviewed to evaluate the role of local surgery in this patient population.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most retrospective studies and meta-analyses report that primary breast surgery is associated with improved prognosis when stage IV disease is first diagnosed. However, significant selection bias exists in these data. Women who undergo surgery tend to be younger, have smaller primary tumors, fewer comorbidities, and lower metastatic burden\u2014particularly fewer visceral metastases. They are also more likely to receive higher-quality overall care. These factors suggest that surgeons preferentially select patients with a better expected prognosis for surgery. In contrast, prospective randomized trials have consistently failed to demonstrate that locoregional surgery provides additional survival benefits beyond systemic therapy alone. Consequently, routine locoregional surgical treatment is not recommended for most patients with\n                      <jats:italic>de-novo<\/jats:italic>\n                      stage IV breast cancer. Nevertheless, a notable exception exists for patients with bone-only metastases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Although retrospective analyses support a survival advantage from locoregional surgery in\n                      <jats:italic>de-novo<\/jats:italic>\n                      stage IV breast cancer, prospective RCTs have not confirmed a benefit for the general patient population. However, locoregional surgery does appear to offer survival benefits for patients with bone-only metastases. Further prospective clinical trial data are certainly needed to better define the value of locoregional surgery in\n                      <jats:italic>de-novo<\/jats:italic>\n                      stage IV breast cancer.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1831950","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:44:41Z","timestamp":1788781481000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in locoregional surgical treatment of de-novo stage IV breast cancer: a review"],"prefix":"10.3389","volume":"16","author":[{"given":"Shushu","family":"Liu","sequence":"first","affiliation":[{"name":"Breast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mancheng","family":"Yu","sequence":"additional","affiliation":[{"name":"Breast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Ke","sequence":"additional","affiliation":[{"name":"Breast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Breast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast cancer center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National key clinical specialty discipline construction program, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","article-title":"Breast cancer: updated and deep insights","volume":"6","author":"Cuthrell","year":"2023","journal-title":"Int Res J Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","article-title":"Awareness and current knowledge of breast cancer","volume":"50","author":"Akram","year":"2017","journal-title":"Biol Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3974-x","article-title":"Ten-year survival in women with primary stage IV breast cancer","volume":"160","author":"Eng","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"B4","article-title":"Breast cancer treatment","volume":"104","author":"Trayes","year":"2021","journal-title":"Am Fam Physician"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/1179554920942440","article-title":"Role of locoregional treatment in de novo stage IV breast cancer","volume":"14","author":"Lee","year":"2020","journal-title":"Clin Med Insights Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-9776(21)00086-2","article-title":"Locally advanced breast cancer","volume":"62","author":"Aebi","year":"2022","journal-title":"Breast"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00687-1","article-title":"Systemic therapy for early-stage breast cancer: learning from the past to build the future","volume":"19","author":"Agostinetto","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0054","article-title":"NCCN guidelines insights: kidney cancer, version 1.2021: featured updates to the NCCN guidelines","volume":"18","author":"Motzer","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s280470","article-title":"Impact of primary site surgery on survival of patients with de novo stage IV breast cancer","volume":"13","author":"Huang","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"18132","DOI":"10.1038\/s41598-020-75119-0","article-title":"Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China","volume":"10","author":"Ma","year":"2020","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21861","article-title":"Treatment modalities in sinonasal undifferentiated carcinoma: an analysis from the national cancer database","volume":"7","author":"Khan","year":"2017","journal-title":"Int Forum Allergy Rhinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4741.2008.00644.x","article-title":"Patient and tumor characteristics associated with primary tumor resection in women with stage IV breast cancer: analysis of 1988-2003 SEER data","volume":"14","author":"Gnerlich","year":"2008","journal-title":"Breast J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.04.2226","article-title":"Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis","volume":"24","author":"Rapiti","year":"2006","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000000368","article-title":"Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies","volume":"263","author":"Petrelli","year":"2016","journal-title":"Ann Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2016.01.253","article-title":"The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: a systematic review and meta-analysis","volume":"42","author":"Paiella","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000007048","article-title":"Surgery of the primary tumor improves survival in women with stage IV breast cancer in Southwest China: a retrospective analysis","volume":"96","author":"Xie","year":"2017","journal-title":"Medicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10549-008-0101-7","article-title":"Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival","volume":"115","author":"Bafford","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2015.4539","article-title":"Initial surgery and survival in stage IV breast cancer in the United States, 1988-2011","volume":"151","author":"Thomas","year":"2016","journal-title":"JAMA Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1245\/aso.2006.03.033","article-title":"Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor","volume":"13","author":"Babiera","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00135-7","article-title":"Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial","volume":"16","author":"Badwe","year":"2015","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-4-318","article-title":"Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy","volume":"11","author":"Montemurro","year":"2006","journal-title":"Oncologist"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/ijc.ijc_484_17","article-title":"Breast cancer in a tertiary cancer center in India: an audit with outcome analysis","volume":"55","author":"Nair","year":"2018","journal-title":"Indian J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2021.08.686","article-title":"Primary surgery with systemic therapy in patients with de novo stage IV breast cancer: 10-year follow-up; protocol MF07-01 randomized clinical trial","volume":"233","author":"Soran","year":"2021","journal-title":"J Am Coll Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.suc.2018.03.009","article-title":"Inflammatory breast cancer: what to know about this unique, aggressive breast cancer","volume":"98","author":"Menta","year":"2018","journal-title":"Surg Clin North Am"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-09621-8","article-title":"The effect of primary surgery in patients with de novo stage IV breast cancer with bone metastasis only (Protocol BOMET MF 14-01): a multi-center prospective registry study","volume":"28","author":"Soran","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1200\/jco.2023.41.16_suppl.523","article-title":"A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017","volume":"42","author":"Shien","year":"2023","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.1960","article-title":"Prognostic impact of 21-gene recurrence score in patients with stage IV breast cancer: TBCRC 013","volume":"34","author":"King","year":"2016","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000002771","article-title":"Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial","volume":"269","author":"Fitzal","year":"2019","journal-title":"Ann Surg"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-09650-3","article-title":"Clinical evidence for locoregional surgery of the primary tumor in patients with de novo stage IV breast cancer","volume":"28","author":"Yu","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0310-0","article-title":"Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression","volume":"29","author":"Petrelli","year":"2012","journal-title":"Med Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1590246","article-title":"Effect of locoregional surgery in primary tumors on overall survival in patients with de novo stage IV breast cancer: a systematic review and meta-analysis","volume":"15","author":"Sun","year":"2025","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijrobp.2011.06.189","article-title":"Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis","volume":"84","author":"Nguyen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14134-7","article-title":"Great debate: the surgeon\u2019s role in locoregional management of stage IV breast cancer","volume":"30","author":"Lucci","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.23.29454","article-title":"Locoregional therapies for primary and metastatic breast cancer: AJR expert panel narrative review","volume":"222","author":"Deipolyi","year":"2024","journal-title":"AJR Am J Roentgenol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3892\/or.2023.8600","article-title":"Aggressive local therapy for de novo metastatic breast cancer: challenges and updates","volume":"50","author":"Liu","year":"2023","journal-title":"Oncol Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"JCO2502600","DOI":"10.1200\/jco-25-02600","article-title":"HER2CLIMB-05: a phase III study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer","volume":"43","author":"Dieras","year":"2025","journal-title":"J Clin Oncol"},{"key":"B37","article-title":"FDG-PET to assess therapeutic response in patients with bone-dominant metastatic breast cancer (FEATURE\/EA1183)","volume":"43","author":"Specht","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12905-025-03667-6","article-title":"Real-world breast cancer treatment patterns and guideline-concordant treatment completion among Malawian women","volume":"25","author":"Morgan","year":"2025","journal-title":"BMC Womens Health"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3889\/oamjms.2021.6052","article-title":"De novo stage IV luminal breast cancer: yes or no for local treatment? Serial cases and review","volume":"9","author":"Karakolevska-Ilova","year":"2021","journal-title":"Open Access Maced J Med Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1083297","article-title":"Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology","volume":"13","author":"Merloni","year":"2023","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02006","article-title":"Early local therapy for the primary site in de novo stage IV breast cancer: results of a randomized clinical trial (E2108)","volume":"40","author":"Khan","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1831950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:44:42Z","timestamp":1788781482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1831950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1831950"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1831950","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1831950"}}